Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$55.37
0.0%
$43.58
$23.00
▼
$59.72
$3.31B1.212.12 million shs1.35 million shs
Baxter International Inc. stock logo
BAX
Baxter International
$25.77
+0.9%
$24.55
$15.73
▼
$30.00
$13.21B0.687.55 million shs4.17 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$319.43
-0.4%
$320.15
$276.01
▼
$362.41
$12.64B0.71393,499 shs365,983 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$30.49
-1.6%
$28.82
$26.12
▼
$37.09
$12.97B0.521.56 million shs1.41 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-0.02%+8.80%+59.94%+13.16%+134.92%
Baxter International Inc. stock logo
BAX
Baxter International
+0.95%-2.45%+1.95%-3.16%+44.98%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.36%-0.63%-0.47%-2.36%+14.59%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
-1.63%-1.50%+4.93%+4.21%-6.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$55.37
0.0%
$43.58
$23.00
▼
$59.72
$3.31B1.212.12 million shs1.35 million shs
Baxter International Inc. stock logo
BAX
Baxter International
$25.77
+0.9%
$24.55
$15.73
▼
$30.00
$13.21B0.687.55 million shs4.17 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$319.43
-0.4%
$320.15
$276.01
▼
$362.41
$12.64B0.71393,499 shs365,983 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$30.49
-1.6%
$28.82
$26.12
▼
$37.09
$12.97B0.521.56 million shs1.41 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-0.02%+8.80%+59.94%+13.16%+134.92%
Baxter International Inc. stock logo
BAX
Baxter International
+0.95%-2.45%+1.95%-3.16%+44.98%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.36%-0.63%-0.47%-2.36%+14.59%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
-1.63%-1.50%+4.93%+4.21%-6.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
2.75
Moderate Buy$57.924.60% Upside
Baxter International Inc. stock logo
BAX
Baxter International
1.86
Reduce$23.27-9.69% Downside
Penumbra, Inc. stock logo
PEN
Penumbra
2.18
Hold$367.0714.91% Upside
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.91
Reduce$31.914.67% Upside

Current Analyst Ratings Breakdown

Latest AXGN, BAX, SNN, and PEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Penumbra, Inc. stock logo
PEN
Penumbra
Reiterated RatingHold$374.00
11/9/2026
Baxter International Inc. stock logo
BAX
Baxter International
Boost Price TargetUnderweight$20.00 ➝ $23.00
11/5/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
DowngradeHold ➝ Strong Sell
10/30/2026
Baxter International Inc. stock logo
BAX
Baxter International
UpgradeSell (D-) ➝ Sell (D)
10/30/2026
Penumbra, Inc. stock logo
PEN
Penumbra
UpgradeHold (C) ➝ Hold (C+)
10/30/2026
Baxter International Inc. stock logo
BAX
Baxter International
Lower Price TargetNeutral$26.00 ➝ $25.00
10/30/2026
Baxter International Inc. stock logo
BAX
Baxter International
Boost Price TargetEqual Weight$23.00 ➝ $25.00
10/29/2026
Baxter International Inc. stock logo
BAX
Baxter International
Reiterated RatingHold$25.00
10/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Boost Price TargetOutperform$52.00 ➝ $56.00
10/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Reiterated RatingBuy$58.00
10/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Boost Price TargetOverweight$50.00 ➝ $60.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$225.21M14.69N/AN/A$8.31 per share6.66
Baxter International Inc. stock logo
BAX
Baxter International
$11.24B1.19$5.74 per share4.49$12.52 per share2.06
Penumbra, Inc. stock logo
PEN
Penumbra
$1.40B8.97$4.28 per share74.58$40.18 per share7.95
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$6.16B2.07$3.38 per share9.03$12.45 per share2.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$15.70M-$0.65N/A425.92N/A-11.96%-5.35%-4.41%N/A
Baxter International Inc. stock logo
BAX
Baxter International
-$957M-$1.41N/A12.703.75-6.23%16.23%5.08%N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$177.69M$3.9780.4652.19N/A10.06%10.39%8.09%N/A
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$625MN/AN/A13.552.10N/AN/AN/AN/A

Latest AXGN, BAX, SNN, and PEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Baxter International Inc. stock logo
BAX
Baxter International
$0.5180$0.58+$0.0620$0.57$2.91 billion$2.98 billion
10/29/2026Q3 2026
Penumbra, Inc. stock logo
PEN
Penumbra
$1.20$1.07-$0.13$1.07$401.41 million$410.15 million
10/28/2026Q3 2026
AxoGen, Inc. stock logo
AXGN
AxoGen
$0.1313$0.21+$0.0787$0.04$73.45 million$75.83 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Baxter International Inc. stock logo
BAX
Baxter International
$0.040.16%-11.54%N/A N/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.591.94%N/AN/AN/A

Latest AXGN, BAX, SNN, and PEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/28/2026
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.010.17%11/27/202611/27/20261/4/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.04
12.02
10.67
Baxter International Inc. stock logo
BAX
Baxter International
1.20
1.79
1.19
Penumbra, Inc. stock logo
PEN
Penumbra
0.01
5.89
3.92
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.62
2.14
1.11

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
2.44%
Baxter International Inc. stock logo
BAX
Baxter International
0.17%
Penumbra, Inc. stock logo
PEN
Penumbra
2.90%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
62259.73 million58.27 millionOptionable
Baxter International Inc. stock logo
BAX
Baxter International
37,500517.35 million516.47 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,70039.41 million38.27 millionOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
16,988418.72 million414.53 millionOptionable

Recent News About These Companies

Smith & Nephew SNATS (NYSE:SNN) Upgraded to Buy at Wall Street Zen
Smith & Nephew SNATS (NYSE:SNN) Cut to Hold at Wall Street Zen
Smith & Nephew SNATS Q3 Earnings Call Highlights
Smith & Nephew Snats (SNN) Gets a Hold from BTIG

New MarketBeat Followers Over Time

Media Sentiment Over Time

AxoGen stock logo

AxoGen NASDAQ:AXGN

$55.37 -0.01 (-0.02%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$55.40 +0.03 (+0.05%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Baxter International stock logo

Baxter International NYSE:BAX

$25.77 +0.23 (+0.90%)
Closing price 11/17/2026 03:59 PM Eastern
Extended Trading
$25.63 -0.14 (-0.55%)
As of 05:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Penumbra stock logo

Penumbra NYSE:PEN

$319.43 -1.19 (-0.37%)
Closing price 11/17/2026 03:59 PM Eastern
Extended Trading
$320.06 +0.64 (+0.20%)
As of 05:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$30.48 -0.49 (-1.57%)
Closing price 11/17/2026 03:59 PM Eastern
Extended Trading
$30.58 +0.10 (+0.31%)
As of 05:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.